Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.720
-0.050 (-1.81%)
At close: Mar 6, 2026, 4:00 PM EST
2.730
+0.010 (0.37%)
After-hours: Mar 6, 2026, 7:46 PM EST
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$999,349
Profits / Employee
-$348,128
Market Cap
640.37M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Emergent BioSolutions | 900 |
| Pacira BioSciences | 790 |
| Cronos Group | 610 |
| Kamada | 420 |
| Ironwood Pharmaceuticals | 253 |
| Aquestive Therapeutics | 142 |
ESPR News
- 3 days ago - Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript - Seeking Alpha
- 4 days ago - Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Business Wire
- 17 days ago - Esperion to Participate in The 2026 Citizens Life Sciences Conference - GlobeNewsWire
- 18 days ago - Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 - GlobeNewsWire
- 23 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha